Business
Jan 12, 2026 · tact.cgkik.top

Revvity says it will exceed 2025 profit forecast range

Jan 12 (Reuters) - Revvity said on Monday it expects ​its 2025 adjusted profit per ‌share to exceed its forecast of $4.90 ‌to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics ⁠services.

The company's ‌shares were up nearly 6% in extended trading.

Pharmaceutical ‍companies have ramped up drug development in the U.S. amid evolving ​trade policies under President Donald ‌Trump.

Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to ⁠data compiled by ​LSEG.

It also expects ​annual revenue to grow 4% to $2.86 billion, above estimates ‍of $2.84 billion.

The ⁠company will report its fourth-quarter and full year 2025 ⁠results on February 2.

(Reporting by Puyaan ‌Singh in Bengaluru; Editing ‌by Leroy Leo)

You Might Also Like

News

Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth

News

In a first, scientists observe a comet reversing its spin

News

Antimatter took to the road for the very first time. Here’s why it matters

News

Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport